Healthcare Industry News: protein therapeutics
News Release - May 1, 2006
Altus Pharmaceuticals Appoints Lauren Sabella Vice President, Commercial DevelopmentCAMBRIDGE, Mass.--(HSMN NewsFeed)--May 1, 2006--Altus Pharmaceuticals Inc. (Nasdaq: ALTU ), a biopharmaceutical company developing and commercializing oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that Lauren Sabella has been appointed Vice President, Commercial Development. In this new position, Ms. Sabella will lead Altus' commercialization activities and report to Sheldon Berkle, President and CEO of Altus.
"Lauren is a senior executive with almost 20 years of experience in the marketing and sale of pharmaceutical products," said Sheldon Berkle. "Lauren's experience, which includes the responsibility for and management of several new pharmaceutical product launches, will be invaluable as Altus progresses our two lead programs ALTU-135 and ALTU-238 through development and to the market. ALTU-135 for pancreatic insufficiency, and ALTU-238, a long acting formulation of human growth hormone currently in a Phase II trial, are both planned to enter pivotal, Phase III, clinical trials in the second half of this year."
Prior to joining Altus, Ms. Sabella was employed by Boehringer Ingelheim Pharmaceuticals for 18 years in positions of increasing responsibility. Most recently Ms. Sabella served as Vice President Sales, Eastern Zone, where she was responsible for leading and managing over 1000 Regional Directors, District Managers and Sales Representatives that generated approximately $2 billion in sales revenue across the company's promoted portfolio. Previously, she was Executive Director, Marketing in Boehringer's Respiratory Medicine area, a key therapeutic franchise with several products including Atrovent®, Combivent®, and Spiriva® indicated for the treatment of COPD. Ms. Sabella also was Director, CNS Marketing, responsible for the launch of Mobic®, a $1 billion product in the US NSAID marketplace, and for Mirapex®, a drug to treat Parkinson Disease. Ms. Sabella holds a B.B.A from Hofstra University.
About Altus Pharmaceuticals Inc.
Altus Pharmaceuticals, headquartered in Cambridge, MA is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com.
Source: Altus Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.